We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The European Medicines Agency’s (EMA) safety committee has recommended revised product safety information for Johnson & Johnson’s (J&J) and Moderna’s COVID-19 vaccines. Read More
Deep decreases from high baseline tau levels were associated with the best clinical response in patients who responded to Aduhelm during clinical trials, according to new data presented at the Alzheimer’s Disease/Parkinson’s Disease 2022 international conference last week in Barcelona, Spain. Read More
Moderna and Pfizer/BioNTech are both pushing to get expanded Emergency Use Authorization (EUA) for a fourth dose/second booster of their COVID-19 vaccines, but a new study questions its effectiveness in the population at large. Read More
Merck’s mega blockbuster Keytruda (pembrolizumab) may soon have a new indication, this time in an earlier stage of disease than is typical for the anti-PD-L1 therapy. Read More
There’s a push by congressional Democrats to get President Biden to issue a host of executive orders as soon as possible on key priorities, including drug pricing, because they’re not convinced they can get legislation passed before the November midterms. Read More
Diversity is a critical area in clinical research that desperately needs to be improved, the pharma industry agrees, but policies that would require sponsors to enroll more diverse populations will backfire, contends industry trade group PhRMA. Read More
Drug compounding pharmacy Ideal Specialty Apothecary of Parsippany, N.J., has received a Form 483 detailing quality deficiencies observed during an FDA inspection from Sept. 13 through Nov. 18, 2021. Read More
Esai’s investigational anti-tau antibody E2841 grabbed some air time yesterday in Barcelona, Spain, with the first detailed look at a phase 2/3 study in people who are genetically predestined to develop Alzheimer’s disease. Read More